11.04.2018 • News

Borealis studies EVA/LDPE Plant in China

Borealis studies EVA/LDPE Plant in China (c) mmmx/Shutterstock
Borealis studies EVA/LDPE Plant in China (c) mmmx/Shutterstock

Vienna-based olefins and polyolefins major Borealis is conducting a feasibility study for an advanced EVA/LDPE plant in China, which would supply specialty applications. Preferred location for the facility is the national petrochemicals park at Dayabay, Huizhou, Guangdong, a center of the Chinese plastics processing industry.

Borealis said it has “a well-established, ongoing cooperation and dialogue with various authorities and stakeholders” at Dayabay to support its growth ambitions.

Driven in particular by solar, wire & cable and other specialty applications, the company cites “strong demand” in the People’s Republic for the products manufactured using the advanced high-pressure process.

The potential investment, said William Yau, senior vice president Asia Growth, , would support Borealis’ long-term strategy “to be truly global petrochemicals company that continues to invest in major growth markets and is close to its global customers.”

For distribution, the Austrian olefins and polyolefins specialist said it can capitalize on the strong marketing and sales network of its Borouge joint venture with Abu Dhabi National Oil Company (ADNOC).                          

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read